Aptose Biosciences (NASDAQ: APTO)
Aptose Biosciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Aptose Biosciences Company Info
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
News & Analysis
Why Aptose Biosciences Stock Is Skyrocketing Today
The company reported very encouraging results from an early-stage study.
Why Aptose Biosciences Stock Sank Today
Dilution is on the way.
3 Ultra-High-Growth Biopharma Stocks to Grab Now
Can the run for Sarepta Therapeutics, Viela Bio, and Aptose Biosciences continue?
Why Aptose Biosciences Stock Sank Today
Investors weren't excited by the biotech's preliminary results from an early-stage clinical study.
Could This Cancer Drug Developer’s Stock Make You Rich?
Investing in this emerging cancer-focused biotech may just allow you to retire early.
Why Aptose Biosciences Shares Are Jumping Today
Investors excited about the biotech's prospects are taking the opportunity to buy on the dip following the announcement of a new stock offering.
Why Aptose Biosciences Shares Jumped Today
Promising preclinical data and the acquisition of another small biotech continued to generate enthusiasm among investors.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.